论文部分内容阅读
胸腺肽α_1(T_α)是一种免疫调节剂,它能诱导淋巴细胞成熟、增强T细胞功能、促进免疫缺陷的重建。1991年Mutchnick等进行的小型试验性研究认为80％的慢性乙型肝炎病人出现临床、免疫学及组织学的改善。然而,1995年美国的一项97例多中心研究显示仅稍有些差异。T_α的疗效尚需证实。为此,作者开展了此项随机、对照临床试验。 病例选择 48例台湾病人年龄16～75岁,HBsAg、HBeAg阳性≥6月,ALT升高,人选3月内肝活检证实为慢性乙型肝炎伴HBcAg阳性表达,HBV DNA至少2
Thymosin α_1 (T_α) is an immunomodulatory agent that induces lymphocyte maturation, enhances T cell function, and promotes the reconstruction of immunodeficiency. In a small pilot study conducted by Mutchnick et al. In 1991, 80% of patients with chronic hepatitis B reported clinical, immunologic and histological improvement. However, a 1995 multicentre study in the United States showed only a slight difference. The efficacy of T_α remains to be confirmed. To this end, the authors conducted this randomized, controlled clinical trial. 48 cases of Taiwan patients aged 16 to 75 years old, HBsAg, HBeAg positive ≥ 6 months, elevated ALT, 3 months of human biopsy confirmed chronic hepatitis B with HBcAg positive expression of HBV DNA at least 2